Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Total Non-Current Liabilities (2023 - 2025)

Tvardi Therapeutics' Total Non-Current Liabilities history spans 3 years, with the latest figure at $1.2 million for Q1 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 94.53% to $1.2 million in Q1 2025 year-over-year; TTM through Mar 2025 was $1.2 million, a 94.53% decrease, with the full-year FY2024 number at -$3.6 million, down 111.43% from a year prior.
  • Total Non-Current Liabilities hit $1.2 million in Q1 2025 for Tvardi Therapeutics, up from -$3.6 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for TVRD hit a ceiling of $31.7 million in Q4 2023 and a floor of -$3.6 million in Q4 2024.
  • Historically, Total Non-Current Liabilities has averaged $13.7 million across 3 years, with a median of $15.6 million in 2024.
  • Biggest five-year swings in Total Non-Current Liabilities: crashed 111.43% in 2024 and later crashed 94.53% in 2025.
  • Tracing TVRD's Total Non-Current Liabilities over 3 years: stood at $31.7 million in 2023, then crashed by 111.43% to -$3.6 million in 2024, then surged by 133.11% to $1.2 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for TVRD at $1.2 million in Q1 2025, -$3.6 million in Q4 2024, and $10.0 million in Q3 2024.